Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2021; 27(28): 4653-4666
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4653
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4653
Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility
Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang, Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang, Key Laboratory of Tumor Epidemiology of Henan Province, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450001, Henan Province, China
Author contributions: Ji XK, He G, Wang KY, Song CH, Zhang JY, and Wang KJ contributed to conception or design of the study; Ji XK, He G, and Wang KY contributed to acquisition of the data; Ji XK, He G, Wang KY, and Wang KJ contributed to analysis or interpretation of the data; Ji XK contributed to drafting of the manuscript; Madhurapantula SV and Wang KJ contributed to critical revision of the manuscript for important intellectual content.
Supported by National Natural Science Foundation of China , No. 81373097 .
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai-Juan Wang, PhD, Professor, College of Public Health, Zhengzhou University, No. 100 Kexue Avenue, Zhengzhou 450001, Henan Province, China.
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: March 7, 2021
Revised: March 17, 2021
Accepted: July 2, 2021
Article in press: July 2, 2021
Published online: July 28, 2021
Processing time: 179 Days and 19.5 Hours
Peer-review started: January 27, 2021
First decision: March 7, 2021
Revised: March 17, 2021
Accepted: July 2, 2021
Article in press: July 2, 2021
Published online: July 28, 2021
Processing time: 179 Days and 19.5 Hours
Core Tip
Core Tip: Cyclooxygenase-2 (COX-2) is considered to be the key inducible enzyme in prostaglandins synthesis, and non-steroidal anti-inflammatory drugs can reduce the risk of malignant tumors of the digestive system by blocking the effect of COX-2. However, COX-2 inhibitors to prevent or treat gastric cancer may be limited because of their cardiovascular side effects. This review will be helpful for early screening and further research to find new approaches to gastric cancer treatment by summarizing the association between whole COX-2 sequence variation and susceptibility to gastric cancer and synthesizing the new progress in understanding the role of COX-2 in gastric carcinogenesis.